FRIENDWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company that improves health through innovative patient care tests, today announced that the company’s medical director, Matthew Goldberg, MD, FAAD, a board-certified dermatologist and dermatopathologist, will present. The Precision Medicine World Conference (PMWC®) 2023 is being held January 25-27 in Santa Clara, California.
Dr. Goldberg’s presentation, “Using Molecular Diagnostics to Guide Cancer Management Decisions,” will be held on Wednesday, January 25 at 2:30 PM PT as part of Track 3: Diagnostics and Molecular Profiling in the Clinic. Dr. Goldberg will highlight several tests in Castle’s skin cancer and gastroenterology portfolios, including DecisionDx®-Melanoma, DecisionDx®-SCC and the TissueCypher® Barrett’s Esophagus test, and show how the personalized information the tests provide can help clinicians make treatment decisions. patient care to improve patient outcomes.
“Castle Biosciences is a leading company in the precision medicine space committed to revolutionizing the management of skin cancer and Barrett’s esophagus,” said Dr. Goldberg. “Focusing on significant unmet clinical disease needs, we use innovative in-house testing platforms to provide significant improvements in diagnostic or risk stratification approaches in the various disease states offered by molecular testing.
“While there is much discussion about the promise of personalized medicine, Castle’s tests have the potential to improve patient outcomes and reduce costs to the healthcare system. I look forward to sharing concrete examples as we discuss how molecular testing technologies can be used clinically to benefit patient care today.” I’m
Dr. Goldberg has served as Castle’s Medical Director since 2020 and supports Castle’s commercial and pipeline trials. He graduated from Princeton University and received his medical degree from the Icahn School of Medicine at Mount Sinai. Dr. Goldberg completed his dermatology residency at the University of California, San Francisco and completed his dermatology fellowship at Texas Southwestern University.
Conference presentation content will be available only to registered attendees. Visit https://www.pmwcintl.com/ for more information and registration details.
About the Precision Medicine World Conference
PMWC, the Precision Medicine World Conference, is the largest and most original annual conference dedicated to precision medicine. PMWC’s mission is to bring together recognized leaders from the healthcare and biotechnology sectors, leading global researchers and medical professionals and innovators, to present practical content that helps bridge the knowledge gap between these various sectors, thereby accelerating cross-functional seeding and collaboration. development and promotion of precision medicine.
Since 2009, PMWC has been recognized as an important platform for all constituents of the healthcare and biotechnology community, providing a unique forum for the exchange of information on the latest advances in technology, clinical implementation, research and all aspects. regulation and compensation sectors.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company that improves health through innovative tests for patient care. The company aims to transform disease management by putting people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancer, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the company has active research and development programs for tests in other diseases with high clinical need, including a test in development to predict response to systemic therapy in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSecDecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSecTissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
This press release contains forward-looking statements that comply with the “safe harbor” established by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, as amended. departments. These forward-looking statements include, but are not limited to, statements regarding: the potential of our tests and the personalized information they provide to improve patient outcomes, reduce treatment costs, and help clinicians make more informed treatment decisions about patient care. health care system and will be clinically available for patient care today. The words “may,” “potential,” and similar words are intended to identify forward-looking statements, but not all forward-looking statements contain these qualifiers. We may not actually achieve the plans, intentions or expectations expressed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events may differ materially from the plans, intentions and expectations expressed in the forward-looking statements we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including: the results and conclusions of further research or testing, including with respect to the diagnostic and prognostic tests discussed in this press release; actual use of our tests may not provide patients with the benefits described above; inadequate coverage or reimbursement of our tests by government and commercial payers may limit our ability to reduce costs to the health care system; and the risks described under the heading “Risk Factors” in our quarterly report on Form 10-Q for the three months ended September 30, 2022 and in our other filings with the SEC. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update forward-looking statements, except as required by law.